WORKSHOP: Partnering for rare disease outcomes - why AI is not enough

WORKSHOP: Partnering for rare disease outcomes - why AI is not enough

Monday, November 2, 2020 9:30 AM to 12:00 PM · 2 hr. 30 min. (Africa/Abidjan)
Pre-congress workshop

Information

NOTE: YOU NEED TO REGISTER (BLUE BUTTON)

While AI is seen as a key factor in patient cohort identification, there remain many barriers to successful execution. These exercises should not simply do the same as previous practice, just faster, better, cheaper, because patients will still remain undiagnosed.

What we will be discussing with other partners in the rare disease and personalised medicines arena, is how we can construct a new way of working that does not solely focus on AI and digital technology, but drives toward greater value across stakeholders: patients, patient groups, healthcare professionals, payers and of course for companies developing and commercialising medicines for smaller populations.

We will share a vision of innovative service delivery and then in the panel session, we will discuss some of the barriers and enablers to change the way we do business and create a more inclusive approach to deliver a future vision of healthcare.

These are pragmatic insights based on our joint experience that we wish to share with the audience so that you may put together smarter programmes of work across your internal departments for better outcomes.

Agenda:

10:30 CET – Welcoming remarks and introductions by Christopher Rudolf, Volv

10:40 CET – How does the Xperiome patient-powered platform personalize the patient’s journey? By Julie Walters, Raremark

11:10 CET – Use of novel AI/ML tools to support patient identification; perspectives from the Syneos Health Rare Disease Consortium by Ray Huml, Syneos Health

11:40 CET – Short break

11:45 CET – How does AI play a piece in this when put together? By Christopher Rudolf, Volv

12:00 – 13:00 CET: Interactive panel discussion with all speakers and LIVE Q&As

Christopher Rudolf, Volv

Alex Garner, Raremark

Ray Huml, Syneos Health

Ron Herings, The Pharmo Institute

13:00 CET Workshop finishes, the next will start 13:00 CET on OMPs.

volv global6Volv was founded to allow customers and partners to exploit latest developments in technology and data science to generate unique and powerful insights from data. Our mission is to speed science, reduce the cost of healthcare, and so enhance the economic output and well-being for all. With inTrigue, Volv deliver accurate insight into rare diseases and targeted medicines enhanced by AI, delivering content to support earlier diagnosis through the discovery of new predictive digital biomarkers. We use high sensitivity proprietary methodologies to detect digital biomarkers across human diseases focussing in areas of significant unmet need or of difficult to diagnose conditions. We transform disease management and treatment for the first time at the level of the individual, especially where the cohorts cannot be easily determined. inTrigue reshapes medical practice, helping specialists make better clinical diagnoses for precision and personalised medicine, so that they can correctly treat the precise cohort of patients that will benefit.

Log in